Hiro Mental Clinic

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Alcohol use disorder2 trials
• Anxiety disorders (generalised anxiety)1 trial
• Bipolar disorder1 trial
• Depression1 trial
• Post-traumatic stress disorder (PTSD)1 trial
• Social anxiety disorder1 trial

Phase

• Phase 33 trials
• Phase 22 trials
• Phase 2/32 trials

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Ono Pharmaceutical Co., Ltd.2 trials
• Otsuka Medical Devices Co., Ltd. Japan1 trial
• Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial
• Sumitomo Pharma America, Inc.1 trial

Running trials

• Recruiting

  A Study of Brenipatide in Participants With Alcohol Use Disorder

  NCT07219953· Phase 3· Eli Lilly and Company· Source

  Contact: Hiroaki Furui (principal investigator)

• Recruiting

  A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

  NCT07219966· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Software as a Medical Device for the Treatment of Patients With PTSD

  NCT06589505· Phase 2/3· Otsuka Medical Devices Co., Ltd. Japan· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alcohol use disorder1 recruiting

Closed trials

• Completed

  A Study of ONO-1110 in Patients With Social Anxiety Disorder

  NCT06805565· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  A Study of ONO-1110 in Patients With Major Depressive Disorder

  NCT06792136· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

  NCT05729373· Phase 2/3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Terminated

  A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

  NCT05227209· Phase 3· Sumitomo Pharma America, Inc.· Source